Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.
Napo said in the notice on the U.S. Health
…
Articles by : Tom Mirga, Editor at Large
340B covered entities are breathing easier today upon learning that U.S. House Democrats excluded much-feared Medicaid managed care “spread pricing” language from forthcoming drug pricing legislation.
The House Energy & Commerce Committee late yesterday released the text of the 16
…
U.S. Health and Human Services Secretary Xavier Becerra yesterday reiterated HHS’ “strong support for the 340B Drug Pricing Program” in a 29-page plan to lower drug prices.
Becerra’s Sept. 9 report to White House domestic and economic policy counselors
…
North Carolina lawmakers approved a final deal Wednesday to protect some, but not all, of the state’s 340B covered entities against discrimination by pharmacy benefit managers (PBMs).
Under an agreement a House-Senate conference committee reached on Sept. 8, 340B
…
The only clear path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.
Urging
…
Hospitals participating in the 340B program provided $67.9 billion in total benefits to their communities in 2018, the American Hospital Association (AHA) reported yesterday. Community benefits represented 13.7% of total 340B hospital expenses, the group said.
AHA broke out
Federal health officials have added New Jersey and New York to the list of states granted 340B enrollment flexibility due to Hurricane Ida.
The U.S. Health Resources and Services Administration (HRSA) posted the notice about the East Coast states’ addition
…
340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.
Entities are telling key members of Congress and their staffs that while they support federal action to
…
Federal health officials “violated unambiguous statutory commands” in 2018 when they lowered lower Medicare Part B drug reimbursement rates for 340B hospitals by nearly 30% and their decision should be set aside, hospital groups and individual hospitals told the U.S.
…
The Arkansas Insurance Department is holding a public hearing this Friday morning on whether it should strike down as unconstitutional the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by
…